Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on GlycoMimetics (GLYC) and Sunesis Pharma (SNSS).
GlycoMimetics (GLYC)
In a report released yesterday, Ritu Baral from Cowen & Co. maintained a Buy rating on GlycoMimetics. The company’s shares closed yesterday at $13.83.
According to TipRanks.com, Baral is a top 100 analyst with an average return of 26.6% and a 49.0% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Allena Pharmaceuticals Inc, and Ionis Pharmaceuticals Inc.
GlycoMimetics has an analyst consensus of Strong Buy, with a price target consensus of $29.50, implying an 113.3% upside from current levels. In a report released yesterday, Roth Capital also maintained a Buy rating on the stock with a $35 price target.
.
See today’s analyst top recommended stocks >>
Sunesis Pharma (SNSS)
Cowen & Co. analyst Marc Frahm maintained a Hold rating on Sunesis Pharma yesterday. The company’s shares closed yesterday at $1.32, close to its 52-week low of $1.21.
According to TipRanks.com, Frahm is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -9.7% and a 33.3% success rate. Frahm covers the Healthcare sector, focusing on stocks such as Merrimack Pharmaceuticals, Adaptimmune Therapeutics, and Gritstone Oncology Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Sunesis Pharma.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
